Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability
Braz. j. med. biol. res
;
40(3): 383-389, Mar. 2007. tab
Article
in English
| LILACS
| ID: lil-441763
ABSTRACT
The effect of proton pump inhibitors and Helicobacter pylori infection on the bioavailability of antibiotics is poorly understood. We determined the effects of 5-day oral administration of 60 mg lansoprazole on the bioavailability of clarithromycin in individuals with and without H. pylori infection. Thirteen H. pylori-infected and 10 non-infected healthy volunteers were enrolled in a study with an open-randomized two-period crossover design and a 21-day washout period between phases. Plasma concentrations of clarithromycin in subjects with and without lansoprazole pre-treatment were measured by liquid chromatography coupled to a tandem mass spectrometer. Clarithromycin Cmax and AUC0-10 h were significantly reduced after lansoprazole administration. In addition, lansoprazole treatment of the H. pylori-positive group resulted in a statistically significant greater reduction in Cmax (40 vs 15 percent) and AUC0-10 h (30 vs 10 percent) compared to lansoprazole-treated H. pylori-negative subjects. Thus, treatment with lansoprazole for 5 days reduced bioavailability of clarithromycin, irrespective of H. pylori status. This reduction, however, was even more pronounced in H. pylori-infected individuals.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Helicobacter pylori
/
Helicobacter Infections
/
Clarithromycin
/
Anti-Ulcer Agents
/
Anti-Bacterial Agents
Type of study:
Controlled clinical trial
/
Observational study
Limits:
Adult
/
Humans
Language:
English
Journal:
Braz. j. med. biol. res
Journal subject:
Biology
/
Medicine
Year:
2007
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Universidade São Francisco/BR
Similar
MEDLINE
...
LILACS
LIS